A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Category Primary study
JournalBLOOD
Year 2022
This article has no abstract
Epistemonikos ID: fd912637ce3635cd830d5426d12d0f172193d705
First added on: Feb 16, 2025